Welcome to Paid Research Studies




  • Condition:   Infection
    Interventions:   Drug: Antibiotic;   Drug: No antibiotics
    Sponsor:   Rush University Medical Center
    Recruiting

  • Conditions:   Urinary Tract Infections;   Recurrent UTI;   Antibiotic Resistant Infection
    Interventions:   Dietary Supplement: Bifidobacterium infantis;   Other: Placebo;   Drug: Antibiotics
    Sponsors:   Ochsner Health System;   Procter and Gamble
    Recruiting

  • Conditions:   Antibiotic Resistant Infection;   Nosocomial Infection;   Pathogen Transmission;   Nutrition Disorders;   Critical Illness;   Sepsis
    Interventions:   Drug: Inulin Oral Suspension;   Drug: Placebo Oral Suspension;   Drug: Broad-spectrum antibiotics
    Sponsor:   Columbia University
    Not yet recruiting

  • Condition:   Chronic Rhinosinusitis (Diagnosis)
    Intervention:   Drug: Topical Antibiotic Nasal Saline Irrigation
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   Clostridium Difficile Infection;   C.Difficile Diarrhea;   CDI
    Interventions:   Drug: Low Dose FMT Capsule DE;   Drug: Single Dose FMT Capsule DE;   Drug: Placebo oral capsule
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Cystitis;   Cystitis;Puerperium;   Pyelonephritis
    Interventions:   Drug: Antibiotic;   Other: Standard Prenatal Care
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting

  • Condition:   Antibiotic Resistant Infection
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Assisted Reproductive Technology;   Antibiotic Prophylaxis;   Embryo Transfer
    Intervention:   Other: Withholding antibiotic prophylaxis
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Occlusion
    Interventions:   Device: Clear Bactiseal 'large' catheter (EVD);   Device: Orange Bactiseal 'small' catheter (EVD)
    Sponsor:   Wake Forest University Health Sciences
    Recruiting

  • Condition:   Malignant Neoplasms of Independent (Primary) Multiple Sites
    Interventions:   Other: Tongue Assessment;   Other: Stool Sample;   Behavioral: Questionnaires;   Device: Holter Monitor;   Other: Yogurt
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting

  • Conditions:   Obesity, Childhood;   Antibiotic Side Effect
    Intervention:  
    Sponsors:   Children's Hospital of Philadelphia;   University of Minnesota - Clinical and Translational Science Institute;   University of Pennsylvania;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Appendicitis
    Interventions:   Other: Non-operative treatment;   Procedure: Appendectomy
    Sponsors:   Children's Mercy Hospital Kansas City;   Provincial Health Services Authority;   Alberta Children's Hospital;   Children's Hospital of Western Ontario;   St. Justine's Hospital;   Children's Hospital of Winnipeg;   Le Bonheur Children's Hospital;   Karolinska University Hospital;   Hospital for Children and Adolescents, Finland;   University of Southampton;   UCL Institute of Child Health;   KK Women's and Children's Hospital;   Uppsala University Children's Hospital
    Recruiting

  • Condition:   Appendicitis
    Intervention:   Other: Non-operative
    Sponsors:   Nationwide Children's Hospital;   Children's Hospital and Health System Foundation, Wisconsin;   Comer Children’ Hospital;   C.S. Mott Children's Hospital;   James Whitcomb Riley Hospital for Children;   Kosair Children’ Hospital;   Ann & Robert H Lurie Children's Hospital of Chicago;   St. Louis Children's Hospital;   American Family Children’s Hospital;   Children's Hospital Medical Center, Cincinnati
    Recruiting

  • Conditions:   Osteoarthritis;   Hip Infection;   Prosthetic Joint Infection;   Complications; Arthroplasty, Infection or Inflammation;   Complications; Arthroplasty
    Interventions:   Procedure: Implantation of a static, non-articulating cement spacer.;   Procedure: Implantation of an articulating spacer.
    Sponsors:   Rush University Medical Center;   Thomas Jefferson University;   Central DuPage Hospital
    Recruiting

  • Conditions:   Obesity;   Induction of Labor Affected Fetus / Newborn
    Interventions:   Drug: Cefazolin;   Drug: Placebo;   Drug: Azithromycin
    Sponsor:   University of Oklahoma
    Recruiting

  • Conditions:   Inflammation at Mini-screw Insertion Site;   Mobility, Mini-screw
    Interventions:   Drug: Amoxicillin;   Drug: Placebo oral capsule
    Sponsor:   St. Louis University
    Recruiting

  • Conditions:   Premalignant Vulvar Lesion;   Benign Vulvar Lesion
    Intervention:   Drug: Cefazolin
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Fractures, Open
    Interventions:   Drug: Tobramycin;   Other: Placebo: normal saline
    Sponsor:   University of Virginia
    Recruiting

  • Condition:   Open Fracture
    Intervention:   Drug: Vancomycin
    Sponsors:   The University of Texas Health Science Center at San Antonio;   United States Army Institute of Surgical Research;   San Antonio Military Medical Center
    Not yet recruiting

  • Condition:   Clostridium Difficile Infection (CDI)
    Interventions:   Drug: Fidaxomicin;   Drug: Vancomycin
    Sponsors:   University of Michigan;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Communication;   Anti-Bacterial Agents;   Decision Making;   Personal Satisfaction
    Interventions:   Behavioral: Education;   Behavioral: Communication Skills
    Sponsors:   Children's Mercy Hospital Kansas City;   Heartland Primary Care of Sunflower Medical Group;   Washington University School of Medicine;   Patient-Centered Outcomes Research Institute
    Recruiting

  • Condition:   Prostate Cancer
    Interventions:   Procedure: Lymph node template;   Procedure: Transverse versus vertical closure;   Drug: antibiotic prophylaxis
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Osteoarthritis;   Knee Infection;   Prosthetic Joint Infection;   Complications; Arthroplasty, Infection or Inflammation;   Complications; Arthroplasty
    Interventions:   Procedure: Static Spacer;   Procedure: Articulating Spacer
    Sponsors:   Rush University Medical Center;   Central DuPage Hospital;   Joint Implant Surgeons, Inc.;   Thomas Jefferson University
    Recruiting

  • Condition:   Surgical Site Infection
    Interventions:   Drug: topical irrigation with the antibiotic bacitracin;   Drug: topical irrigation with sterile normal saline (NS);   Drug: intravenous (IV) prophylactic antibiotic
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting

  • Condition:   Prosthesis-Related Infections
    Intervention:   Other: Oral Antibiotics
    Sponsor:   Rush University Medical Center
    Recruiting

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Placebo for antibiotic;   Drug: Vancomycin pretreatment;   Drug: Nivolumab;   Drug: Matching Placebo for SER-401;   Drug: SER-401
    Sponsors:   Parker Institute for Cancer Immunotherapy;   Seres Therapeutics, Inc.
    Recruiting

  • Condition:   Chronic Sinus Infection
    Intervention:   Drug: Amoxi Clavulanate
    Sponsor:   Montefiore Medical Center
    Recruiting

  • Condition:   Lower Respiratory Tract Infection
    Interventions:   Drug: Azithromycin;   Other: Placebo;   Device: VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Colorectal Neoplasms;   Diverticulitis;   Inflammatory Bowel Diseases;   Surgical Site Infection
    Interventions:   Drug: Polyethylene Glycol;   Drug: Neomycin;   Drug: Metronidazole Hydrochloride;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   Thomas Jefferson University
    Recruiting

  • Condition:   Facial Defect
    Intervention:   Drug: cephalexin
    Sponsor:   University of Michigan
    Recruiting

  • Condition:   Pneumonia
    Interventions:   Drug: Murepavadin;   Drug: One anti-pseudomonal antibiotic
    Sponsor:   Polyphor Ltd.
    Recruiting

  • Condition:   Ulcerative Colitis (UC)
    Interventions:   Other: Ulcerative Colitis Diet;   Drug: Antibiotic cocktail
    Sponsor:   Prof. Arie Levine
    Recruiting

  • Conditions:   Obstetric Complication;   Postpartum Hemorrhage;   Postpartum Endometritis
    Interventions:   Drug: CeFAZolin 1000 MG;   Drug: Clindamycin 900 MG in 6 ML Injection
    Sponsor:   Cedars-Sinai Medical Center
    Recruiting

  • Conditions:   Intestinal Microbiome;   Febrile Neutropenia
    Interventions:   Drug: Piperacillin-tazobactam;   Drug: cefepime
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Supracondylar Humerus Fracture;   Post Operative Wound Infection
    Interventions:   Drug: Cefazolin;   Drug: Clindamycin;   Drug: Saline
    Sponsors:   Sumit Gupta;   University of Missouri-Columbia
    Recruiting

  • Conditions:   Enterocolitis, Necrotizing;   Bacteremia;   Bronchopulmonary Dysplasia;   Intraventricular Hemorrhage;   Periventricular Leukomalacia;   Chronic Lung Disease;   Retinopathy of Prematurity;   Ileal Perforation
    Interventions:   Drug: Antibiotic;   Other: Gastric fluid;   Other: Breast milk;   Other: Stool samples;   Drug: Antibiotics - pre-emptive;   Other: Skin swabs
    Sponsors:   University of Florida;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Society for Pediatric Dermatology
    Recruiting

  • Condition:   Ulcerative Colitis
    Interventions:   Biological: Fecal Microbiota Transplantation (FMT), OpenBiome;   Other: pretreatment antibiotics
    Sponsor:   Najwa Elnachef
    Recruiting

  • Condition:   Salivary Duct
    Intervention:   Drug: Postoperative Oral Antibiotics (Clindamycin or Augmentin)
    Sponsors:   Our Lady of the Lake Hospital;   Louisiana State University Health Sciences Center in New Orleans
    Recruiting

  • Condition:   Urinary Tract Infection (UTI)
    Interventions:   Other: Routine Care;   Other: INSPIRE CPOE Smart Prompt
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
    Recruiting

  • Condition:   Pneumonia
    Interventions:   Other: INSPIRE CPOE Smart Prompt;   Other: Routine Care
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
    Recruiting

  • Condition:   Catheter-related Infections
    Interventions:   Drug: Mino-Lok;   Drug: Antibiotic lock
    Sponsor:   Leonard-Meron Biosciences, Inc.
    Recruiting

  • Condition:   Antibiotic Stewardship
    Intervention:   Other: Opt-Out Protocol
    Sponsor:   Duke University
    Recruiting

  • Condition:   Pulmonary Cystic Fibrosis
    Intervention:   Drug: Standard of care IV antibiotic(s)
    Sponsors:   Chris Goss;   Cystic Fibrosis Foundation;   CF Therapeutics Development Network Coordinating Center;   Medical University of South Carolina;   University of Washington
    Recruiting

  • Conditions:   Ventilator Associated Pneumonia;   Nosocomial Infections in Children;   Microbial Colonization
    Intervention:   Behavioral: Development and implementation of an antibiotic guideline
    Sponsors:   Virginia Commonwealth University;   The Gerber Foundation
    Recruiting

  • Condition:   Bacteremia
    Interventions:   Drug: DSTA4637S;   Drug: Placebo;   Drug: SOC
    Sponsor:   Genentech, Inc.
    Recruiting

  • Condition:   Wound Infection
    Intervention:   Other: PO versus IV antibiotics Route of administration evaluation
    Sponsor:   Major Extremity Trauma Research Consortium
    Recruiting

  • Conditions:   Overactive Bladder;   Urinary Tract Infections
    Interventions:   Procedure: Periprocedural Antibiotics;   Drug: Extended Antibiotics;   Procedure: Injection of OnabotulinumtoxinA (BTX-A)
    Sponsors:   Vanderbilt University Medical Center;   The Allergan Foundation;   Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction
    Recruiting

  • Conditions:   Appendicitis;   Perforated Appendicitis;   Ruptured Appendicitis;   Complicated Appendicitis
    Interventions:   Procedure: Early Appendectomy;   Procedure: Interval Appendectomy;   Drug: Antibiotics
    Sponsor:   University of Michigan
    Recruiting

  • Condition:   Bacterial Pneumonia
    Interventions:   Drug: Cefiderocol;   Drug: Standard of Care Antibiotic
    Sponsor:   Shionogi
    Recruiting

  • Conditions:   Arthropathy of Knee;   Antibiotic Prophylaxis
    Intervention:   Drug: Cefazolin
    Sponsors:   Duke University;   American Association of Hip and Knee Society
    Recruiting

  • Condition:   Rabies Human
    Interventions:   Biological: Rabies Vaccine;   Drug: Metronidazole;   Drug: Vancomycin;   Drug: Neomycin Sulfate
    Sponsor:   Emory University
    Recruiting

  • Conditions:   Antibiotic Side Effect;   Eyelid; Wound;   Eyelid Diseases;   Surgical Wound Infection;   Surgical Wound, Recent;   Surgical Incision;   Skin Cancer Face;   Antibiotic Allergy;   Surgical Site Infection
    Interventions:   Drug: Topical Anti-Infective Product;   Drug: Topical Ointment
    Sponsor:   University of California, San Francisco
    Recruiting

  • Conditions:   Antibiotics;   Pituitary Adenoma
    Interventions:   Drug: Placebo;   Drug: Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
    Sponsors:   St. Joseph's Hospital and Medical Center, Phoenix;   Thomas Jefferson University;   The Cleveland Clinic
    Recruiting

  • Condition:   Breast Cancer
    Interventions:   Drug: Chlorhexidine irrigation;   Drug: triple antibiotic irrigation
    Sponsor:   Vanderbilt University Medical Center
    Recruiting

  • Condition:   Kidney Stones
    Interventions:   Drug: cephalosporins;   Drug: aminoglycoside;   Drug: metronidazole;   Drug: Clindamycin;   Drug: aminoglycoside/ sulbactam;   Drug: Fluoroquinolones
    Sponsor:   Northwell Health
    Recruiting

  • Conditions:   Sick Sinus Syndrome;   Complete Heart Block;   Syncope;   Chronic Systolic Heart Failure
    Interventions:   Drug: polymixin/bacitracin;   Drug: cephalexin, or levofloxacin, or clindamycin;   Drug: Saline
    Sponsors:   Vanderbilt University Medical Center;   Thomas Jefferson University;   The Cooper Health System;   Valley Health System;   Medtronic
    Recruiting

  • Condition:   Latent Tuberculosis
    Interventions:   Drug: Rifapentine 600 mg orally;   Drug: Isoniazid 900 mg orally;   Drug: Pyridoxine 50 mg orally
    Sponsor:   St. Louis University
    Recruiting

  • Conditions:   Idiopathic Infantile Hypercalcaemia - Severe Form;   Genetic Disease;   Hypercalcemia, Idiopathic, of Infancy;   Hypercalciuric Hypercalcemia;   Idiopathic Infantile Hypercalcemia - Mild Form;   Hypercalciuria
    Intervention:   Drug: Rifampin
    Sponsors:   Children's Hospital of Philadelphia;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Pneumonia
    Interventions:   Drug: Murepavadin;   Drug: Two anti-pseudomonal antibiotics
    Sponsor:   Polyphor Ltd.
    Recruiting

  • Condition:   RSV Infection
    Interventions:   Drug: EDP-938;   Drug: Itraconazole;   Drug: Rifampin;   Drug: Quinidine
    Sponsors:   Enanta Pharmaceuticals;   Pharmaceutical Research Associates
    Recruiting

  • Conditions:   Sinusitis;   Respiratory Tract Infections
    Interventions:   Drug: Amoxicillin-clavulanate;   Drug: Placebo
    Sponsors:   University of Pittsburgh;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Human Immunodeficiency Virus I Infection
    Intervention:   Drug: Mycophenolate Mofetil 500Mg Tab
    Sponsors:   Fred Hutchinson Cancer Research Center;   University of Washington
    Recruiting

  • Condition:   Spinal Cord Injury
    Interventions:   Drug: D-Cycloserine;   Drug: Placebo;   Other: Training;   Other: Stimulation;   Other: Placebo Stimulation
    Sponsors:   University of Miami;   The Craig H. Neilsen Foundation
    Recruiting

  • Conditions:   Kidney Transplant;   Renal Transplant Recipients
    Interventions:   Biological: DCreg: 0.5 million cells/kg+SOC;   Biological: DCreg: 1.2 million cells/kg+SOC;   Biological: DCreg:2.5 to 5.0 million cells/kg+SOC
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   University of Pittsburgh
    Not yet recruiting

  • Conditions:   Kidney Transplantation;   Renal Transplantation;   Renal Transplant Recipient
    Interventions:   Biological: Donor-derived Mesenchymal Stromal Cells;   Drug: alemtuzumab;   Drug: belatacept;   Drug: sirolimus;   Drug: mycophenolate mofetil;   Drug: mycophenolate acid;   Drug: prednisone
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting

  • Condition:   Gout Chronic
    Interventions:   Drug: Pegloticase 8 MG/ML [Krystexxa];   Drug: MMF;   Drug: Placebo
    Sponsors:   University of Alabama at Birmingham;   University of Michigan
    Recruiting

  • Condition:   Healthy Volunteer
    Interventions:   Drug: Ozanimod;   Drug: Gemfibrozil;   Drug: Itraconazole;   Drug: Rifampin
    Sponsor:   Celgene
    Recruiting

  • Conditions:   Kidney Transplant Rejection;   Gastrointestinal Disorder, Functional
    Interventions:   Drug: Everolimus;   Drug: Mycophenolic Acid
    Sponsors:   Washington University School of Medicine;   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Renal Transplantation;   Mesenchymal Stem Cells
    Interventions:   Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion;   Other: Normal Saline (Placebo) Infusion
    Sponsors:   Ahmed Osama Gaber, MD;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Conditions:   Low Back Pain;   Pain
    Interventions:   Drug: D-cycloserine;   Drug: Placebo
    Sponsors:   Northwestern University;   United States Department of Defense
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
    Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Interstitial Lung Disease;   ILD;   Systemic Sclerosis;   Scleroderma
    Interventions:   Drug: Bortezomib;   Drug: Placebo;   Drug: Mycophenolate mofetil
    Sponsors:   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Lymphoid Leukemia;   Lymphoma;   Leukemia;   Myeloma;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndromes;   Recurrent Acute Myeloid Leukemia, Adult;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia;   Acute Myelogenous Leukemia
    Interventions:   Drug: mycophenolate mofetil;   Biological: Sargramostim;   Biological: Filgrastim
    Sponsors:   Virginia Commonwealth University;   Massey Cancer Center
    Recruiting

  • Condition:   SCI
    Interventions:   Behavioral: hypoxia;   Behavioral: sham hypoxia;   Drug: D-cycloserine;   Drug: sham-NMDA agonist;   Behavioral: exercise training
    Sponsor:   VA Office of Research and Development
    Not yet recruiting

  • Condition:   Gulf War Illness
    Interventions:   Drug: D-cycloserine;   Drug: Placebos
    Sponsor:   Boston University Charles River Campus
    Recruiting

  • Condition:   Type 1 Diabetes Mellitus
    Intervention:   Drug: Myfortic
    Sponsor:   Rodolfo Alejandro
    Recruiting

  • Condition:   Healthy Volunteers
    Interventions:   Drug: Vemlidy (tenofivir alafenamide);   Drug: Priftin (rifapentine);   Drug: Isoniazid;   Dietary Supplement: Pyridoxine
    Sponsor:   National Institutes of Health Clinical Center (CC)
    Recruiting

  • Condition:   PTSD
    Interventions:   Behavioral: CBT + ImRs;   Behavioral: CBT + I.E.;   Drug: D-Cycloserine;   Drug: Placebo;   Drug: Study Pill
    Sponsors:   Boston University Charles River Campus;   James S McDonnell Foundation
    Recruiting

  • Condition:   Kidney Transplant; Complications
    Interventions:   Drug: Extended Release Tacrolimus Tablets;   Drug: Immediate Release Tacrolimus Capsule
    Sponsors:   Roy D. Bloom, MD;   Veloxis Pharmaceuticals
    Not yet recruiting

  • Condition:   Diarrhea
    Interventions:   Drug: Entocort;   Drug: Placebos
    Sponsor:   Pooja Budhiraja, MD
    Recruiting

  • Condition:   Systemic Sclerosis
    Interventions:   Drug: Belimumab;   Drug: Rituximab;   Other: Placebo Subcutaneous Injection;   Other: Placebo Infusion;   Drug: MMF
    Sponsors:   Hospital for Special Surgery, New York;   GlaxoSmithKline
    Recruiting

  • Condition:   Healthy Volunteers
    Interventions:   Drug: rifapentene (RPT);   Drug: darunavir/cobicistat (DRV/c);   Drug: Isoniazid (INH);   Dietary Supplement: Pyridoxine
    Sponsor:   National Institutes of Health Clinical Center (CC)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Hyperkalemia;   Kidney Transplant
    Intervention:   Drug: Patiromer
    Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorder;   Chronic Lymphocytic Leukemia;   B-cell Lymphoma;   T-cell Lymphoma;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Chronic Myelomonocytic Leukemia
    Interventions:   Radiation: Total body irradiation (TBI);   Drug: Anti-thymocyte globulin (ATG);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Radiation: Total lymphoid irradiation (TLI)
    Sponsor:   Stanford University
    Recruiting

  • Condition:   End Stage Renal Disease
    Intervention:   Drug: Tacrolimus Extended Release Oral Capsule
    Sponsors:   Cedars-Sinai Medical Center;   Astellas Pharma Inc
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Sickle Cell Disease;   Sickle Cell Disorder;   Hemoglobinopathies;   Thalassemia;   Anemia, Sickle Cell
    Interventions:   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Rabbit anti-thymocyte globulin;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
    Sponsors:   City of Hope Medical Center;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Leukemia
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: Filgrastim
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Acute Lymphocytic Leukemia (ALL);   Severe Aplastic Anemia
    Intervention:   Genetic: umbilical cord blood (UCB)
    Sponsor:   West Virginia University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia;   Myeloproliferative Disorder;   Myelofibrosis;   Lymphoma;   Lymphoma, Non-Hodgkin;   Plasma Cell Disorder
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Drug: Tacrolimus;   Drug: cellcept;   Drug: g-csf;   Procedure: Peripheral Blood Transplant
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Lung Transplant Rejection;   Antibody-mediated Rejection
    Interventions:   Drug: Belatacept;   Drug: Tacrolimus;   Drug: ATG;   Drug: Mycophenolate Mofetil;   Drug: Methylprednisolone;   Drug: Prednisone
    Sponsors:   Washington University School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI);   Bristol-Myers Squibb
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Other: Haploidentical Stem Cell Transplantation
    Sponsor:   Loyola University
    Recruiting

  • Condition:   Myelofibrosis
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Radiation: Total Body Irradiation (TBI);   Procedure: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Sorafenib;   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Filgrastim;   Drug: Mycophenolate mofetil
    Sponsors:   M.D. Anderson Cancer Center;   Bayer
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   CD45-Positive Neoplastic Cells Present;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Pretargeted Radioimmunotherapy;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: Busulfan;   Drug: Rituximab;   Drug: ATG;   Drug: Fludarabine;   Drug: Clofarabine;   Radiation: Total Body Irradiation;   Procedure: Cord Blood Transplant;   Drug: Mycofenolate mofetil;   Drug: Tacrolimus;   Drug: Filgrastim-sndz;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Mesna
    Sponsors:   M.D. Anderson Cancer Center;   Mesoblast, Inc.
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure;   Immunosuppression
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Condition:   Hematologic Malignancy
    Interventions:   Drug: melphalan;   Drug: fludarabine;   Drug: thiotepa;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Mycophenolate Mofetil;   Drug: Filgrastim;   Drug: Tacrolimus
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Spinal Cord Injury
    Interventions:   Drug: Seromycin;   Device: STDP;   Other: Training;   Drug: Dextromethorphan;   Drug: Seromycin Placebo;   Drug: Dextromethorphan Placebo;   Device: Sham STDP
    Sponsors:   VA Office of Research and Development;   University of Miami
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Sirolimus;   Drug: Fludarabine;   Radiation: Total body irradiation;   Procedure: Hematopoietic stem cell transplant
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Transplant; Failure, Kidney;   EBV
    Interventions:   Drug: belatacept;   Drug: Tacrolimus;   Drug: MPA
    Sponsors:   Lorenzo Gallon;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Thymoglobulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Procedure: Bone marrow infusion;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Biological: Donor mesenchymal stem cell infusions
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   B-Cell Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Therapeutic Allogeneic Lymphocytes;   Radiation: Total Nodal Irradiation
    Sponsors:   Robert Lowsky;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   MDS;   Myelofibrosis;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation;   Other: Hematopoietic stem cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate;   Drug: G-CSF
    Sponsor:   Rafic Farah, MD
    Recruiting

  • Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hematologic Malignancy
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Total Marrow Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Posttraumatic Stress Disorder
    Interventions:   Drug: DCS;   Other: Placebo
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Leukemia;   Myeloproliferative Diseases
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Procedure: Expanded NK Cell Infusion;   Procedure: Bone Marrow Transplant;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Radiation: Total Body Irradiation (TBI)
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas
    Recruiting

  • Conditions:   Sickle Cell Disease;   Hemoglobinopathies
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide (CTX);   Drug: Mesna;   Drug: Sirolimus;   Drug: Mycophenolate mofetil (MMF);   Procedure: Bone marrow transplantation;   Radiation: Total body irradiation
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Recruiting

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: Mycophenolate mofetil
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting

  • Conditions:   Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
    Interventions:   Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
    Sponsors:   University of California, Davis;   Spectrum Pharmaceuticals, Inc
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Post-Transplant Lymphoproliferative Disorder;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Radiation: Indium In-111 Ibritumomab Tiuxetan;   Drug: Mycophenolate Mofetil;   Other: Pharmacological Study;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Lenalidomide;   Drug: Fludarabine monophosphate;   Drug: Melphalan;   Procedure: NK Infusion;   Procedure: CB Infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Rituximab;   Drug: Cyclophosphamide
    Sponsors:   M.D. Anderson Cancer Center;   Celgene;   American Cancer Society, Inc.;   CLL Global Research Foundation
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Busulfan;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
    Interventions:   Biological: Thymus Tissue for Transplantation;   Procedure: Blood Draw;   Drug: Rabbit anti-thymocyte globulin;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methylprednisolone or Prednisolone;   Drug: Basiliximab;   Drug: Mycophenolate mofetil
    Sponsors:   M. Louise Markert;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Enzyvant Therapeutics GmbH
    Available

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Fludarabine;   Drug: Cytoxan;   Radiation: Total Body Irradiation;   Procedure: Allogeneic Blood or Marrow Transplant;   Procedure: Peripheral Blood Stem Cell Transplant;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neurological Disorder;   Autoimmune Diseases
    Interventions:   Drug: Mycophenolate Mofetil;   Drug: Azathioprine
    Sponsors:   Duke University;   Beth Israel Deaconess Medical Center;   Patient-Centered Outcomes Research Institute
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
    Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Kidney Transplantation;   Immunosuppression
    Interventions:   Drug: Tacrolimus Extended Release Oral Tablet [Envarsus];   Drug: Mycophenolate Mofetil;   Drug: Mycophenolic Acid Oral Product;   Drug: Tacrolimus;   Drug: Methylprednisolone;   Drug: Prednisone;   Drug: Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]
    Sponsors:   Simon Tremblay, PharmD, PhD;   Veloxis Pharmaceuticals
    Not yet recruiting

  • Condition:   Idiopathic Pulmonary Fibrosis, Acute Fatal Form
    Interventions:   Drug: Autoantibody Reductive Therapy;   Drug: Treatment as Usual (TAU)
    Sponsors:   University of Alabama at Birmingham;   National Heart, Lung, and Blood Institute (NHLBI);   Brigham and Women's Hospital;   Temple University;   University of Pittsburgh
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Donor;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Lymphocytic Leukemia;   Loss of Chromosome 17p;   Myelodysplastic/Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Aggressive Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Atorvastatin Calcium;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Calcinosis Cutis
    Interventions:   Drug: Sodium Thiosulfate;   Other: Saline Solution
    Sponsor:   University of Central Florida
    Recruiting

  • Conditions:   Dermatomyositis;   Idiopathic Inflammatory Myopathies
    Intervention:   Drug: Sodium Thiosulfate
    Sponsor:   National Institute of Environmental Health Sciences (NIEHS)
    Recruiting

  • Conditions:   Gastric Adenocarcinoma;   Esophagogastric Junction;   Gastric Cancer
    Interventions:   Procedure: Surgery;   Drug: Cisplatin;   Drug: Mitomycin C;   Drug: Sodium Thiosulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Liver Transplantation
    Interventions:   Biological: Anti-Thymocyte Globulin - Rabbit;   Biological: darTreg Infusion;   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Anti-Infective Prophylaxis;   Procedure: Leukapheresis;   Procedure: Blood draws;   Procedure: Liver biopsies;   Procedure: Liver transplantation
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Pneumonia
    Interventions:   Drug: Amoxicillin;   Drug: Amoxicillin-clavulanate;   Drug: Cefdinir;   Other: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Myelodysplastic Syndrome;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Myelodysplastic Syndrome;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aggressive Non-Hodgkin Lymphoma;   Beta-2-Microglobulin Greater Than 3 g/mL;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   Chromosome 13 Abnormality;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Immunodeficiency Syndrome;   Non-Cancer Diagnosis;   Severe Aplastic Anemia
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Oligoastrocytoma;   Recurrent Adult Brain Neoplasm
    Interventions:   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mannitol;   Drug: Melphalan;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Advanced Solid Neoplasm
    Interventions:   Drug: Pevonedistat;   Drug: Rifampin;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Paclitaxel
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Glioma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide Phosphate;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Appendicitis
    Interventions:   Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin;   Procedure: Appendectomy
    Sponsors:   University of Washington;   Patient-Centered Outcomes Research Institute
    Recruiting

  • Condition:   Central Nervous System Lymphoma
    Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Mannitol;   Drug: Methotrexate;   Other: Quality-of-Life Assessment;   Biological: Rituximab;   Drug: Sodium Thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Diffuse Large B-Cell Lymphoma;   Adult Myelodysplastic Syndrome;   Adult Non-Hodgkin Lymphoma;   Aggressive Non-Hodgkin Lymphoma;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia;   Childhood Diffuse Large B-Cell Lymphoma;   Childhood Myelodysplastic Syndrome;   Childhood Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Hematopoietic and Lymphoid Cell Neoplasm;   Mantle Cell Lymphoma;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Kidney Transplant;   Adult Living Donor Kidney Transplant Recipients;   Renal Transplant;   Living Kidney Donor
    Interventions:   Biological: Polyclonal Regulatory T Cells;   Biological: Donor-Alloantigen-Reactive Regulatory T Cells;   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Mycophenolic acid;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Procedure: Biopsy, Kidney;   Procedure: Blood Draw;   Procedure: Leukapheresis;   Procedure: IS regimen conversion
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Non-Malignant
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Mycobacterium Avium Complex;   Nontuberculous Mycobacterium Infection
    Interventions:   Drug: Azithromycin;   Drug: Ethambutol;   Drug: Rifampin
    Sponsors:   Kevin Winthrop;   Patient-Centered Outcomes Research Institute;   National Jewish Health;   The University of Texas Health Science Center at Tyler;   University Health Network, Toronto;   New York University;   Medical University of South Carolina;   Mayo Clinic;   Georgetown University;   University of Chicago;   Louisiana State University Health Sciences Center in New Orleans;   University of California, San Diego;   Stanford University;   University of Kansas;   Vancouver Clinic;   University of California, San Francisco;   University of Washington;   Johns Hopkins University;   University of Miami;   Emory University;   University of Iowa;   The Oregon Clinic;   University of North Carolina;   Yale University;   Weill Medical College of Cornell University;   Columbia University;   The University of Texas Health Science Center at San Antonio
    Not yet recruiting

  • Conditions:   Osteomyelitis;   Diabetes;   Amputation
    Interventions:   Drug: Rifampin;   Drug: Riboflavin Placebo
    Sponsor:   VA Office of Research and Development
    Recruiting

  • Conditions:   Systemic Lupus Erythematosus;   Lupus Nephritis
    Interventions:   Drug: KZR-616;   Drug: Placebo
    Sponsor:   Kezar Life Sciences, Inc.
    Recruiting

  • Conditions:   Scleroderma, Systemic;   Interstitial Lung Disease
    Interventions:   Drug: Pirfenidone (PFD);   Drug: Placebo (Plac);   Drug: Mycophenolate Mofetil (MMF)
    Sponsors:   Michael Roth;   University of Michigan;   Genentech, Inc.;   University of California, Los Angeles
    Recruiting

  • Condition:   Uveitis
    Interventions:   Biological: Adalimumab (ADA);   Drug: Conventional immunosuppression (CON)
    Sponsor:   JHSPH Center for Clinical Trials
    Not yet recruiting

  • Condition:   Carcinoma, Hepatocellular
    Interventions:   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Myfortic;   Drug: CellCept;   Drug: Imuran
    Sponsor:   Baylor Research Institute
    Recruiting

  • Conditions:   Pediatric Heart Transplantation;   Immunosuppression;   Chronic Kidney Diseases;   Cardiac Allograft Vasculopathy;   Heart Transplant Failure and Rejection;   Post-transplant Lymphoproliferative Disorder;   Heart Transplant Infection
    Interventions:   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsors:   Boston Children’s Hospital;   Stanford University;   United States Department of Defense
    Recruiting

  • Condition:   Heart Transplant
    Interventions:   Biological: tocilizumab;   Biological: Placebo;   Drug: Standard of Care Triple IS
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Age-Related Macular Degeneration
    Interventions:   Drug: ASP7317;   Other: Placebo;   Drug: tacrolimus;   Drug: mycophenolate mofetil (MMF)
    Sponsor:   Astellas Institute for Regenerative Medicine
    Recruiting

  • Condition:   Graft-versus-host Disease (GVHD)
    Interventions:   Drug: Ruxolitinib;   Drug: Extracorporeal photopheresis (ECP);   Drug: Low-dose methotrexate (MTX);   Drug: Mycophenolate mofetil (MMF);   Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus);   Drug: Infliximab;   Drug: Rituximab;   Drug: Pentostatin;   Drug: Imatinib;   Drug: Ibrutinib
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Myelodysplastic Syndrome (MDS);   Chronic Lymphocytic Leukemia (CLL);   Chemotherapy-sensitive Lymphoma;   Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma;   Acute Myelogenous Leukemia (AML);   Acute Biphenotypic Leukemia (ABL);   Acute Undifferentiated Leukemia (AUL)
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;   Radiation: Total Body Irradiation (TBI) 200cGy on Day -1;   Procedure: Infusion of non-T-cell depleted bone marrow on Day 0;   Drug: Busulfan;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4;   Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1;   Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;   Drug: Sirolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Drug: Pre-HCT Mesna on Days -6 and -5;   Drug: Pre-HCT Mesna on Days -2 and -1;   Drug: Pre-HCT Mesna on Days -5 and -4;   Drug: Post-HCT Mesna
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program;   Resource for Clinical Investigation in Blood and Marrow Transplantation
    Recruiting

  • Conditions:   Kidney Transplantation;   Focal Segmental Glomerulosclerosis (FSGS)
    Interventions:   Drug: Bleselumab;   Drug: Basiliximab;   Drug: Mycophenolate Mofetil (MMF);   Drug: Tacrolimus Capsules;   Drug: Methylprednisone;   Drug: Prednisone
    Sponsors:   Astellas Pharma Global Development, Inc.;   Kyowa Hakko Kirin Co., Ltd
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Conditions:   Sickle Cell Disease;   Graft Versus Host Disease
    Interventions:   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Methylprednisolone;   Drug: Meperidine;   Drug: Alemtuzumab;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Abatacept;   Procedure: Marrow infusion;   Drug: Sirolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Monica Bhatia
    Recruiting

  • Condition:   Kidney Transplant
    Interventions:   Biological: Infliximab;   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Biological: Thymoglobulin;   Drug: Acetaminophen;   Drug: Loratadine;   Biological: Placebo for Infliximab;   Drug: Prednisone;   Drug: Diphenhydramine
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation
    Recruiting

  • Condition:   HIV Infections
    Interventions:   Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Condition:   Systemic Scleroderma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer ALK-positive;   Non-Small Cell Lung Cancer c-Met Dependent;   Non-Small Cell Lung Cancer ROS Marker Positive;   Systemic Anaplastic Large-Cell Lymphoma;   Advanced Malignancies Except Leukemia
    Interventions:   Drug: PF-02341066;   Drug: Rifampin;   Drug: Itraconazole
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Calciphylaxis
    Interventions:   Drug: Sodium Thiosulfate;   Drug: Placebo-Normal Saline
    Sponsor:   Hope Pharmaceuticals
    Recruiting